ADA:
The Effect of Orlistat on Glycemic Control Is Independent of Weight
Loss
Blood
glucose improvements independent of weight loss.
Orlistat
(ORL) in conjunction with a mildly reduced-calorie diet is associated
with improvements in glycemic control, lipid profile and blood
pressure and significant weight loss in patients with type 2 diabetes
(T2D).
The
mean change from baseline in body weight was comparable in ORL- and
PL-treated patients. However, compared to PL-treated patients, ORL-treated
patients had a significantly greater decrease in both HbA1c
and FPG (LSM differences were -0.43% and -0.85 mmol/L respectively). A
regression analysis demonstrated that the change in glycemic control
in ORL-treated patients was significantly less correlated to weight
loss than for PL-treated patients.
In
conclusion, much of the glycemic improvements in ORL- compared to
PL-treated patients are independent effects not related to weight
loss. American
Diabetes Association's 62nd Annual Scientific Sessions
